AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
Last update at 2026-03-10T15:36:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Income before tax | -15.02900M | -21.63200M | -24.43900M | -17.36300M |
| Minority interest | - | - | - | - |
| Net income | -14.22500M | -20.13200M | -21.68600M | -15.01200M |
| Selling general administrative | 0.46M | 0.38M | 0.56M | 0.34M |
| Selling and marketing expenses | - | - | - | - |
| Gross profit | 1.78M | 1.53M | 0.61M | 0.71M |
| Reconciled depreciation | 1.70M | 2.31M | 2.84M | 1.49M |
| Ebit | - | - | - | - |
| Ebitda | - | - | - | - |
| Depreciation and amortization | - | - | - | - |
| Non operating income net other | - | - | - | - |
| Operating income | -15.47400M | -20.45800M | -26.10900M | -17.32700M |
| Other operating expenses | - | - | - | - |
| Interest expense | 0.31M | 0.33M | 0.35M | 0.16M |
| Tax provision | -0.80400M | -1.50000M | -2.75300M | -2.35100M |
| Interest income | 0.40M | 0.46M | 0.14M | 0.03M |
| Net interest income | 0.09M | 0.14M | -0.21800M | -0.12800M |
| Extraordinary items | - | - | - | - |
| Non recurring | - | - | - | - |
| Other items | - | - | - | - |
| Income tax expense | - | - | - | - |
| Total revenue | 2.86M | 2.19M | 1.04M | 1.01M |
| Total operating expenses | 18.34M | 22.64M | 27.15M | 18.34M |
| Cost of revenue | 1.08M | 0.66M | 0.43M | 0.30M |
| Total other income expense net | - | - | - | - |
| Discontinued operations | - | - | - | - |
| Net income from continuing ops | -14.22500M | -20.13200M | -21.68600M | -15.01200M |
| Net income applicable to common shares | - | - | - | - |
| Preferred stock and other adjustments | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Total assets | 25.46M | 31.18M | 49.87M | 47.31M |
| Intangible assets | 0.44M | 0.53M | 0.56M | 1.37M |
| Earning assets | - | - | - | - |
| Other current assets | - | - | - | - |
| Total liab | 7.02M | 8.24M | 9.80M | 6.99M |
| Total stockholder equity | 18.44M | 22.94M | 40.06M | 40.33M |
| Deferred long term liab | - | - | - | - |
| Other current liab | - | - | - | - |
| Common stock | - | - | - | - |
| Capital stock | 32.26M | 26.06M | 26.06M | 23.51M |
| Retained earnings | -133.14500M | -122.32800M | -103.70200M | -83.80800M |
| Other liab | - | - | - | - |
| Good will | 2.21M | 2.21M | 2.21M | 2.21M |
| Other assets | - | - | - | - |
| Cash | 10.43M | 16.22M | 31.90M | 31.84M |
| Cash and equivalents | - | - | - | - |
| Total current liabilities | 3.26M | 3.94M | 5.25M | 4.91M |
| Current deferred revenue | - | - | - | - |
| Net debt | - | - | - | - |
| Short term debt | - | - | - | - |
| Short long term debt | - | - | - | - |
| Short long term debt total | - | - | - | - |
| Other stockholder equity | - | - | - | - |
| Property plant equipment | - | - | - | - |
| Total current assets | 16.41M | 21.22M | 38.63M | 39.37M |
| Long term investments | - | - | - | - |
| Net tangible assets | - | - | - | - |
| Short term investments | - | - | - | - |
| Net receivables | 0.77M | 0.73M | 0.32M | 0.20M |
| Long term debt | - | - | - | - |
| Inventory | 1.58M | 1.68M | 2.06M | 1.75M |
| Accounts payable | 0.69M | 1.06M | 1.50M | 1.12M |
| Total permanent equity | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - |
| Accumulated other comprehensive income | - | - | - | - |
| Additional paid in capital | - | - | - | - |
| Common stock total equity | - | - | - | - |
| Preferred stock total equity | - | - | - | - |
| Retained earnings total equity | - | - | - | - |
| Treasury stock | - | - | - | - |
| Accumulated amortization | - | - | - | - |
| Non currrent assets other | - | - | - | - |
| Deferred long term asset charges | - | - | - | - |
| Non current assets total | 9.05M | 9.97M | 11.24M | 7.95M |
| Capital lease obligations | 4.21M | 4.55M | 5.00M | 2.34M |
| Long term debt total | - | - | - | - |
| Breakdown | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
| Investments | -0.04800M | -0.20100M | -1.75100M | 14.77M |
| Change to liabilities | - | - | - | - |
| Total cashflows from investing activities | - | - | - | - |
| Net borrowings | - | - | - | - |
| Total cash from financing activities | - | - | - | - |
| Change to operating activities | - | - | - | - |
| Net income | -14.22500M | -20.13200M | -21.68600M | -15.01200M |
| Change in cash | -5.82800M | -15.78600M | 0.29M | 19.75M |
| Begin period cash flow | 16.22M | 31.90M | 31.84M | 12.08M |
| End period cash flow | 10.43M | 16.22M | 31.90M | 31.84M |
| Total cash from operating activities | -13.44800M | -14.45800M | -16.05000M | -14.01000M |
| Issuance of capital stock | 8.63M | 0.01M | 19.05M | 19.69M |
| Depreciation | 1.70M | 2.31M | 2.84M | 1.49M |
| Other cashflows from investing activities | - | - | - | - |
| Dividends paid | - | - | - | - |
| Change to inventory | 0.15M | 0.09M | -0.58000M | -1.01500M |
| Change to account receivables | - | - | - | - |
| Sale purchase of stock | - | - | - | - |
| Other cashflows from financing activities | - | - | - | - |
| Change to netincome | - | - | - | - |
| Capital expenditures | 0.44M | 0.66M | 1.89M | 1.79M |
| Change receivables | - | - | - | - |
| Cash flows other operating | - | - | - | - |
| Exchange rate changes | - | - | - | - |
| Cash and cash equivalents changes | - | - | - | - |
| Change in working capital | -1.13200M | -1.03100M | -1.61400M | 0.61M |
| Stock based compensation | 1.45M | 1.89M | 4.39M | 1.32M |
| Other non cash items | -0.06700M | -0.12700M | 0.23M | 0.13M |
| Free cash flow | -13.89200M | -15.11800M | -17.93700M | -15.79800M |
Sector: Healthcare Industry: Diagnostics & Research
| Company | Change (GBX) | Price (GBX) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| CLBX CelLBxHealth plc |
0.10 11.11% | 1.00 | - | - | 7.00 | 1.67 | 6.81 | -1.6211 |
| IDHC Integrated Diagnostics Holdings PLC |
-0.0001 0.02% | 0.59 | 0.18 | 12.89 | 0.0006 | 2.89 | 0.06 | 0.21 |
| DXRX Diaceutics PLC |
- -% | 145.00 | - | 19.72 | 3.52 | 1.85 | 2.71 | 17.28 |
| ABDX Abingdon Health Plc |
0.55 7.59% | 7.80 | - | 67.57 | 2.08 | 3.20 | 1.91 | -0.2499 |
| VRCI Verici Dx Plc |
0.007 1.22% | 0.58 | - | - | 851.60 | 3.00 | 637.86 | -1.1703 |
CelLBxHealth plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis; and Parsortix PR1 system captures and harvests circulating tumour cells from blood. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal circulating tumour cells; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including CTC enrichment and liquid biopsy analysis services; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. CelLBxHealth plc has a strategic partnership with BioView Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use pan-cancer next generation sequencing (NGS) panel. The company was formerly known as ANGLE plc and changed its name to CelLBxHealth plc in October 2025. CelLBxHealth plc was founded in 1994 and is based in Guildford, the United Kingdom.
Surrey Research Park, Guildford, United Kingdom, GU2 7AF
| Name | Title | Year Born |
|---|---|---|
| Ms. Sinéad Eithne Armstrong | Finance Director & Secretary | NA |
| Ms. Michelle Munson | Chief of Staff | NA |
| Dr. Lauren Arthy-Miles | ESG Lead | NA |
| Dr. Cristina Ciccioli | Head of Assay Development | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Please wait processing your request...